An Open-Label Positron-Emission Tomography (PET) Study to Determine Brain Exposure of AZD1390 After Intravenous Administration of a Microdose [11C]AZD1390 to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2018
At a glance
- Drugs AZD 1390 (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 23 Feb 2018 Status changed from active, no longer recruiting to completed.
- 15 Jan 2018 Planned End Date changed from 10 Jan 2018 to 16 Jan 2018.
- 15 Jan 2018 Planned primary completion date changed from 10 Jan 2018 to 16 Jan 2018.